Arv in 2 year old
Reading File
Finding Sources
Finding Sources
Searching PubMed
antiretroviral therapy children pediatric HIV
Finding Sources
Finding Sources
Searching the Web
ARV antiretroviral therapy 2 year old child WHO guidelines 2024 regimen
Reading Web Page
https://hiv.guidelines.org.au/arv-pediatric/what-start/regim…
Finding Sources
Reading Web Page
https://aahivm.org/wp-content/uploads/2025/02/Guidelines-for…
Searching the Web
WHO 2024 ARV first line regimen children under 3 years dolutegravir abacavir lamivudine
Here is a comprehensive summary of ARV (antiretroviral) therapy in a 2-year-old child with HIV, based on current guidelines (DHHS Pediatric HIV Guidelines updated June/December 2024, WHO 2021/2024 recommendations):
Antiretroviral Therapy (ARV) in a 2-Year-Old Child
When to Start ART
ART should be initiated immediately (rapid initiation) in all children with HIV, regardless of CD4 count or clinical stage. This applies to a 2-year-old as well. If diagnosis has been made but ART not yet started, monitor virologic, immunologic, and clinical status every 3-4 months and start ART as soon as possible (AI recommendation).
Regimen Structure
A standard pediatric ARV regimen consists of:
- 2 NRTIs (the "backbone") + one INSTI (preferred) or NNRTI or boosted PI
Preferred Regimens for Children Aged ≥2 Years (2024 DHHS Guidelines)
The choice depends on whether the child can swallow pills or not, and on weight.
For children who cannot swallow pills (most 2-year-olds):
| Regimen | Formulation | Weight Requirement |
|---|---|---|
| DTG + ABC + 3TC (dispersible FDC - Triumeq PD) | PREFERRED | 6 kg to <25 kg; must be HLA-B*5701 negative |
| DTG film-coated tablet (Tivicay) + ABC + 3TC/FTC in liquid | Alternative | ≥25 kg |
| BIC/FTC/TAF (Biktarvy) | Preferred | ≥14 kg (can swallow pills) |
A 2-year-old (typically 10-15 kg) who cannot swallow pills: the top choice is ABC/DTG/3TC dispersible tablets (Triumeq PD), once daily - IF HLA-B*5701 negative.
WHO Preferred Regimen (Low/Middle-Income Countries)
- ABC + DTG + 3TC - recommended as the preferred first-line regimen for pediatric patients from ≥4 weeks of age and weighing ≥3 kg, including a 2-year-old
- The pADL dispersible FDC (Abacavir 60 mg / Dolutegravir 5 mg / Lamivudine 30 mg per tablet) is the formulation being rolled out globally
Alternative Regimens for This Age Group
| Regimen | Notes |
|---|---|
| 2 NRTIs + NVP (nevirapine) | Alternative; older regimen, more toxicity |
| 2 NRTIs + LPV/r (Lopinavir/ritonavir) | Well-established in <3 years; liquid formulation available; many experts still prefer it up to age 3 |
| 2 NRTIs + RAL (raltegravir) | RAL chewable tablets for ≥2 years |
| 2 NRTIs + EFV (efavirenz) | NOT approved for <3 years |
NRTI Backbone Options
- ABC + 3TC (abacavir + lamivudine) - preferred backbone when INSTI-based; requires HLA-B*5701 testing before use
- ZDV + 3TC (zidovudine + lamivudine) - alternative; use if HLA-B*5701 positive
- TAF + FTC - for children weighing ≥14 kg
Important Practical Points for a 2-Year-Old
| Point | Detail |
|---|---|
| HLA-B*5701 testing | Mandatory before starting abacavir - hypersensitivity reaction risk |
| Formulation | Liquid, chewable, or dispersible tablets preferred (most 2-year-olds cannot swallow pills) |
| Adherence | Critical; caregiver education is essential; once-daily regimens improve adherence |
| Drug resistance testing | Do before initiating ART if possible |
| Baseline labs | CBC, LFTs, renal function, CD4 count, viral load, HLA-B*5701 |
| Follow-up | VL and CD4 at 4 weeks, 3 months, then every 3-6 months when stable |
Summary Table: Age ≥2 Years, Cannot Swallow Pills (WHO & DHHS 2024)
| Priority | Regimen | Formulation |
|---|---|---|
| PREFERRED | ABC + DTG + 3TC (if HLA-B*5701 -ve) | Triumeq PD dispersible tablet, once daily |
| Alternative | ZDV + 3TC + NVP | Liquids/syrups |
| Alternative | ABC + 3TC + LPV/r | Liquids (LPV/r widely used <3 yrs) |
| Alternative | ABC + 3TC + RAL | Chewable tabs (≥2 yrs) |
Note: Always confirm local national program guidelines, as treatment availability varies by country. ABC/DTG/3TC as dispersible tablets is the current WHO-preferred global standard for children ≥2 years.
This is a shared conversation. Sign in to Orris to start your own chat.